Complement C3aR signaling: Immune and metabolic modulation and its impact on Alzheimer's disease

Manasee Gedam1, Hui Zheng1

  • 1Department of Molecular and Human Genetics, Huffington Center on Aging, Baylor College of Medicine, Houston, Texas, USA.

PubMed

Insights

Alzheimer's disease involves complement C3a receptor (C3aR) signaling, which modulates immune and metabolic functions. Understanding C3aR is key to developing new Alzheimer's therapies.

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia, characterized by amyloid plaques and neurofibrillary tangles.
  • Incomplete understanding of AD pathogenesis hinders effective therapeutic development.
  • Glial cell and immune system hyperactivation, including the complement cascade, are implicated in AD.

Purpose of the Study:

  • To review the structure, signaling, and function of the C3a receptor (C3aR) in Alzheimer's disease.
  • To elucidate the multifaceted role of C3aR signaling in AD pathogenesis.
  • To inform future research and therapeutic strategies for AD.

Main Methods:

  • Review of cellular studies.
  • Analysis of Alzheimer's disease mouse models.
  • Examination of complement C3aR structure, ligand interaction, and intracellular signaling pathways.

Main Results:

  • C3aR signaling plays a significant role in AD.
  • C3aR acts as a critical immune and metabolic modulator influencing AD.
  • Insights from cellular and animal models highlight C3aR's complex involvement.

Conclusions:

  • C3aR is a key player in Alzheimer's disease pathogenesis.
  • Targeting C3aR signaling offers potential therapeutic avenues for AD.
  • Further research into C3aR's role is crucial for developing novel treatments.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
28